We are delighted to share with you the full agenda below for the WuXi Healthcare Forum 2022, taking place virtually on April 26-28. More than 50 distinguished global leaders will be speaking at this year’s forum, where thousands of colleagues from around the world will unite once again under this year’s theme, “Call To Action,” to support the World Health Organization’s key initiatives in tackling global health challenges head-on, and to collaboratively advance better healthcare solutions.
Complimentary and open to the global healthcare innovation ecosystem, this 3-day program will premiere via Zoom from 8am-11am PDT (11am-2pm EDT) daily from April 26-28. To accommodate our global audience, all registrants will be provided with a link to the on-demand recording of this event. Please log on https://bit.ly/3ucMOgt to register this event and log on https://bit.ly/3jL4Oc5 for speaker bios and program updates.
AGENDA (The times below are AM, Pacific Daylight Time | Virtual via Zoom)
Day 1, April 26
8:00 Welcome & Opening Remarks
Hui Cai, Program Chair, VP & Head of Content, WuXi AppTec Steve Yang, Co-CEO, WuXi AppTec
8:10 Chronic Diseases: Rising to the Challenge A conversation between Sir Menelas Pangalos, EVP & President, BioPharmaceuticals R&D, AstraZeneca, and Steve Yang, Co-CEO, WuXi AppTec
8:30 Global Health: From Partnership to Worldwide Access A conversation between Emilio Emini, CEO, Bill & Melinda Gates Medical Research Institute, and Zina Affas Besse, Deputy Head, Healthcare Private Equity, AXA Investment Managers Group
8:50 Call to Action: The Neuro Challenge Walter Koroshetz, Director, National Institute of Neurological Disorders & Stroke, National Institutes of Health
9:10 Call to Action: The Cardiovascular Challenge A conversation between Mariell Jessup, Chief Science & Medical Officer, American Heart Association, and Faiez Zannad, Emeritus Professor of Therapeutics & Cardiology, Université de Lorraine, Inserm; Chairman, CVCT, Paris, France
9:35 Call to Action: The Cancer Challenge A conversation between Harold Burstein, Institute Physician, Dana-Farber Cancer Institute; Professor of Medicine, Harvard Medical School, Arif Kamal, Chief Patient Officer, American Cancer Society; Physician Quality & Outcomes Officer, Duke Cancer Institute, and Tony Mok, Li Shu Fan Professor of Clinical Oncology, The Chinese University of Hong Kong
10:10 Spotlight on Antimicrobial Resistance Erin Duffy, Chief of Research & Development, CARB-X Valeria Gigante, Team Lead, AMR Division, World Health Organization, Geneva, Switzerland Timothy Jinks, Head of Infectious Diseases Interventions, The Wellcome Trust Henry Skinner, CEO, AMR Action Fund Session Leader: Jenny Yip, Managing Partner, Adjuvant Capital
11:00 Day 1 Adjourn
Day 2, April 27
8:00 Welcome & Opening Remarks
Richard Soll, Head of Boston Office & Senior Advisor of Strategic Projects, WuXi AppTec Minzhang Chen, Co-CEO, WuXi AppTec
8:10 Better. Faster. Smarter.
Stephen Hahn, CEO-Partner, Flagship Pioneering; CEO, Harbinger Health
8:30 Moving the Needle on Neurological Disorders Laurence Barker, Partner, The Dementia Discovery Fund Christina Isacson, Partner, Lightstone Ventures Philip Scheltens, Head, Dementia Fund, EQT Life Sciences Session Leader: Rana Al-Hallaq, Partner, Pfizer Ventures
9:05 Spotlight on Parkinson’s Disease
A conversation between Todd Sherer, EVP, Research Strategy, The Michael J. Fox Foundation for Parkinson’s Research, and Andrew Siderowf, Hurtig-Stern Professor in Neurology, University of Pennsylvania Perelman School of Medicine
9:30 Revitalizing Cardiovascular R&D
Sekar Kathiresan, CEO, Verve Therapeutics Michael Mendelsohn, Founder & Chairman, Cardurion Pharmaceuticals Christopher de Souza, Director, Broadview Ventures Claudia Ulbrich, CEO & Co-Founder, Cardior Pharmaceuticals Session Leader: Simone Fishburn, VP & Editor in Chief, BioCentury Inc.
10:15 Reaching the Next Frontiers in Cancer Therapies Rajesh Chopra, Venture Partner, Head of Oncology, Apple Tree Partners Adam Friedman, President, Corporate Strategy & Business Development, Scorpion Therapeutics Luba Greenwood, CEO, Kojin Therapeutics KT Moortgat, Healthcare Venture Investor, Investment Partner, Droia Ventures Lewis Williams, Co-founder, Chairman & CEO, Walking Fish Therapeutics, Inc.
Session Leader: Dave Madge, VP of Discovery Services, WuXi AppTec
11:00 Day 2 Adjourn
Day 3, April 28
8:00 Welcome & Opening Remarks
Jocelyne Bath, Managing Director, OXGENE Richard Connell, SVP & US / EU COO, WuXi AppTec
8:10 Healthcare 2030: Current and Future Drivers of Success A conversation between William Hait, EVP, Chief External Innovation, Medical Safety & Global Public Health Officer, Johnson & Johnson, and Julie Grant, General Partner, Canaan
8:30 Spotlight on Singapore: The Asia-Pacific Translation Hub for Cell and Gene Therapy in Oncology Andrew Bruce, CEO, MediSix Therapeutics Wee Joo Chng, Executive Director, Singapore Translational Cancer Consortium; Director & Senior Consultant, National University Cancer Institute, Singapore, NUHS Boon Tong Koh, Executive Director, Bioprocessing Technology Institute, A*STAR, Singapore Francesca Lim, Assistant Medical Director, Cell Therapy Facility, Health Science Authority (HSA); Senior Consultant Hematologist, Singapore General Hospital Yann Chong Tan, Managing Director, EVX Ventures; CEO, Nuevocor; CSO, Cargene Therapeutics Session Leader: Danny Soon, CEO, Consortium for Clinical Research & Innovation, Singapore; Executive Director, Singapore Clinical Research Institute
9:30 Spotlight on UK: The Life Science Cluster Standing on the Shoulders of Giants Opening Remarks by Steve Bates, CEO, UK BioIndustry Association Billy Boyle, Co-Founder & CEO, Owlstone Medical Ryan Cawood, CSO, WuXi Advanced Therapies & OXGENE Kathryn Corzo, COO, bit.bio Jack O’Meara, CEO, Ochre Bio Session Leader: Michael Ward, Global Head of Life Sciences & Healthcare Thought Leadership, Clarivate
10:30 When Technology Meets Healthcare
Vineeta Agarwala, General Partner, Andreessen Horowitz Rohit Chandra, Chief Digital Officer, Cleveland Clinic Daphne Koller, CEO & Founder, insitro Session Leader: Ben Robbins, Venture Partner, GV
11:20 Forum Adjourn